News

AFT Pharma reports growth and global expansion

FINANCIAL RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2023

AFT welcomes US FDA approval for sale of Maxigesic IV^®

AFT Pharmaceuticals announces the US FDA has approved Maxigesic IV®, the intravenous form of its patented pain relief medicine, for sale in the US, which represents AFT’s second FDA approval within one year.

AFT Pharmaceuticals to announce half year interim results

AFT Pharmaceuticals announced today that it intends to release on Thursday November 23 2023 its half year interim results for the period ended September 30 2023.

AFT appoints Andrew Lane as independent director

AFT Pharmaceuticals today announces the appointment of Andrew Lane as an independent non-executive director.

Retirement of Jon Lamb

Independent director Jon Lamb today retired from the board following his announcement at the ASM.

AFT Orphan Pharmaceuticals judgment

AFT Pharmaceuticals advises of the release yesterday evening by the High Court at Auckland of its judgment upholding in part claims by PBL Solutions Limited (PBL) against AFT, and dismissing others.

Filter

05/05/2015

NZ pharmacists concerned about codeine-based analgesics

Some text

05/05/2015

Doctors have alternatives to topical antibitoc treatments

Some text

28/10/2009

Kiwi Co. pops pill into US$20b pain-relief market

New Zealanders will find a home-grown answer to pain relief on the shelves at their local pharmacy this month with the launch of a new drug that represents a world breakthrough.